Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of lopinavir/ritonavir + lamivudine versus standard therapy in treatment-naive HIV-1 infection
2010-023008-29Phase 3Completed
- Sponsor
- Fundación Huésped
- Start
- Nov 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lopinavir, ritonavir and lamivudine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Fundación Huésped. Primary endpoint: Virologic suppression at week 48. Started Nov 2010; status: completed.
02
Drugs
lopinavirritonavirlamivudine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2010-023008-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023008-29.